KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 119 filers reported holding KALVISTA PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 2.17 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $963,000 | -74.6% | 100,000 | -50.0% | 0.32% | -62.5% |
| Q4 2020 | $3,798,000 | -13.8% | 200,000 | -42.9% | 0.85% | -33.6% |
| Q3 2020 | $4,407,000 | +4.1% | 350,000 | 0.0% | 1.27% | +14.1% |
| Q2 2020 | $4,235,000 | +58.1% | 350,000 | 0.0% | 1.12% | +57.3% |
| Q1 2020 | $2,678,000 | -63.8% | 350,000 | -15.7% | 0.71% | -49.6% |
| Q4 2019 | $7,391,000 | +102.3% | 415,000 | +31.7% | 1.41% | +51.2% |
| Q3 2019 | $3,654,000 | -45.0% | 315,000 | +5.0% | 0.93% | -32.4% |
| Q2 2019 | $6,645,000 | -42.0% | 300,000 | -25.0% | 1.38% | -53.9% |
| Q1 2019 | $11,448,000 | +36.4% | 400,000 | -5.9% | 2.99% | -1.8% |
| Q4 2018 | $8,394,000 | +68.7% | 425,000 | +88.9% | 3.05% | +188.2% |
| Q3 2018 | $4,975,000 | – | 225,000 | – | 1.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |